Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 52 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
47 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Asahi Kasei Bioprocess Europe from Schaarbeek, company number BE0480190679, closed financial year 2025 with a result of € 6 million after tax. For that financial year Asahi Kasei Bioprocess Europe recorded revenue of € 125.6 million and equity of € 7.6 million. Compared with financial year 2024, the result moved from € 5 million to € 6 million. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 22, 2025.
€ 7.6 million
▼ 44% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 6 million
▲ 20% vs 2024
Profit after tax over the fiscal year.
€ 13.1 million
▲ 41% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 12 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
16.9
▲ 0.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 4 million
▲ 4% vs 2024
€ 236,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 550,221
▼ 11% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 53.5 million
▼ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 172 days on average.
€ 802,993
▼ 19% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 129,061,198 | € 135,659,221 | € 121,958,665 | € 125,565,322 | ▲ 3% |
| Profit after taxes | € 11,091,368 | € 8,351,028 | € 4,971,074 | € 5,978,520 | ▲ 20% |
| Equity | € 8,253,786 | € 16,604,815 | € 13,575,888 | € 7,554,408 | ▼ 44% |
| Total debts | € 63,721,239 | € 77,652,957 | € 60,170,979 | € 66,342,554 | ▲ 10% |
| Cash | € 19,745,285 | € 28,507,099 | € 9,317,616 | € 13,122,343 | ▲ 41% |
| Retained profit | € 7,753,786 | € 16,104,815 | € 13,075,888 | € 7,054,408 | ▼ 46% |
| Dividend | € 17,000,000 | € 0 | € 8,000,000 | € 12,000,000 | ▲ 50% |
| Balance sheet total | € 71,975,025 | € 94,270,012 | € 73,746,868 | € 73,950,982 | |
| Employees (FTE) | 15.7 | 16 | 16.3 | 16.9 | ▲ 0.6 |
Key figures of Asahi Kasei Bioprocess Europe, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to Asahi Kasei Bioprocess Europe?
What happened at Asahi Kasei Bioprocess Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Atsuo Kubota stepped down as director. NBB
- Yusuke Kanazawa stepped down as director. NBB
- Masahi Yamamoto stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 6 million (▲ 20% vs 2024). Source: NBB ↗
- Atsuo Kubota became a director. NBB
- Yusuke Kanazawa became a director. NBB
- Masahi Yamamoto became a director. NBB
- New establishment in Schaarbeek. KBO
In short
From € 11.1 million profit in 2022 to € 6 million profit in 2025.
Paid € 10.5 million in corporate taxes since 2022.
Best year ever: 2022, with € 11.1 million profit.
Paid out € 37 million in dividends to the owners in total.
A new publication or filing at Asahi Kasei Bioprocess Europe? We notify you, reason included.
Follow Asahi Kasei Bioprocess EuropeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Asahi Kasei Medical Co. Ltd (100%).
Directors
According to the 2025 annual accounts
Atsuo Kubota
Director
since 2024 · until 2030
Yusuke Kanazawa
Director
since 2023 · until 2028
Masahi Yamamoto
Director
since 2021 · until 2026
Shareholders
Asahi Kasei Medical Co. Ltd
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Auguste Reyerslaan 70
1030 Schaarbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 47 companies are registered at this address.
All companies at this address →Openbaar Centrum voor Maatschappelijk Welzijn van Schaarbeek
Belgische federatie van de chemische industrie en van life sciences
€ 3.8 million revenue · 2025
Industrie van Vernissen, Stopverven, Drukinkten en Verven voor de Schone Kunst
€ 81,567 gross margin · 2024
FEDERATION INTERNATIONALE Du LAIT
€ 710,637 gross margin · 2025
BIOPLUS-PROBOIS
+42 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0480.190.679
- VAT number
- BE 0480.190.679
- Registered office
- Auguste Reyerslaan 70, 1030 Schaarbeek
- Names & denominations
- Asahi Kasei Bioprocess Europe
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 9 May 2003
- Peppol
- Active · Active since 29 Nov 2025
- Activities · NACE
Markt- en opinieonderzoek
Marktonderzoekbureaus
Groothandel in farmaceutische en medische artikelen
Overige technische testen en toetsen
Overige detailhandel in nieuwe artikelen neg
Overige gespecialiseerde detailhandel in artikelen, andere dan voedingsmiddelen, n.e.g.
Technische testen en analyses